LY3938577

DRUG3 trials

Sponsors

Eli Lilly and Company

Conditions

Diabetes Mellitus, Type 2HealthyType 1 Diabetes MellitusType 2 Diabetes Mellitus

Phase 1

A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

CompletedNCT06132126

Eli Lilly and CompanyHealthy, Type 2 Diabetes Mellitus

Start: 2023-11-17End: 2024-06-28Updated: 2024-07-24

A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)

RecruitingNCT06280703

Eli Lilly and CompanyHealthy, Type 1 Diabetes Mellitus

Start: 2024-05-15End: 2026-09-01Target: 118Updated: 2026-01-20

Phase 2

A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

RecruitingNCT07215312

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2025-10-13End: 2026-12-01Target: 100Updated: 2026-03-02